Skip to content

Study · Animal study (in vivo) · mouse · 2022

12 results

Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.

Xie S, Zhang M, Shi W, Xing Y, Huang Y, Fang WX, Liu SQ, Chen MY, Zhang T, Chen S, Zeng X, Wang S, Deng W, Tang Q

Journal of the American Heart Association29 Sept 2022Cited by 33 (Europe PMC)

PMID36172969 (opens in a new tab)PMCIDPMC9673690 (opens in a new tab)DOI10.1161/jaha.122.026728 (opens in a new tab)PepBankPUB-36172969
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, dulaglutide ameliorated insulin resistance compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide reduced insulin resistance compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInsulin resistance
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    In type 2 diabetes mouse model, dulaglutide ameliorated insulin resistance, improved glucose tolerance, reduced hyperlipidemia, and promoted fatty acid use in the myocardium.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, dulaglutide improved glucose tolerance compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide improved glucose tolerance compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose tolerance
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    In type 2 diabetes mouse model, dulaglutide ameliorated insulin resistance, improved glucose tolerance, reduced hyperlipidemia, and promoted fatty acid use in the myocardium.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, dulaglutide reduced hyperlipidemia compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide reduced high blood fats compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHyperlipidemia
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    In type 2 diabetes mouse model, dulaglutide ameliorated insulin resistance, improved glucose tolerance, reduced hyperlipidemia, and promoted fatty acid use in the myocardium.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, dulaglutide promoted myocardial fatty acid use compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide increased heart fatty acid use compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMyocardial fatty acid use
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    In type 2 diabetes mouse model, dulaglutide ameliorated insulin resistance, improved glucose tolerance, reduced hyperlipidemia, and promoted fatty acid use in the myocardium.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, dulaglutide attenuated cardiac remodeling compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide reduced heart remodeling compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCardiac remodeling
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    Dulaglutide treatment functionally attenuated cardiac remodeling and dysfunction and promoted metabolic reprogramming in diabetic mice.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, dulaglutide attenuated cardiac dysfunction compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide reduced heart dysfunction compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCardiac dysfunction
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    Dulaglutide treatment functionally attenuated cardiac remodeling and dysfunction and promoted metabolic reprogramming in diabetic mice.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, dulaglutide promoted metabolic reprogramming compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide promoted metabolic reprogramming compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMetabolic reprogramming
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    Dulaglutide treatment functionally attenuated cardiac remodeling and dysfunction and promoted metabolic reprogramming in diabetic mice.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, dulaglutide reinstated cardiac mitochondrial morphology compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide restored heart mitochondrial structure compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableCardiac mitochondrial morphology
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    Furthermore, dulaglutide improved mitochondria fragmentation in myocytes, and simultaneously reinstated mitochondrial morphology and function in diabetic hearts.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, dulaglutide reinstated cardiac mitochondrial function compared with vehicle.

    In plain wordsIn mice with diabetes, dulaglutide restored heart mitochondrial function compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableCardiac mitochondrial function
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    Furthermore, dulaglutide improved mitochondria fragmentation in myocytes, and simultaneously reinstated mitochondrial morphology and function in diabetic hearts.
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, dulaglutide preserved AMP-activated protein kinase α2-dependent mitochondrial homeostasis.

    In plain wordsIn mice with diabetes, dulaglutide preserved kinase-dependent mitochondrial balance compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAMPK-dependent mitochondrial homeostasis
    Study

    micen: not reported in source

    High-fat diet/streptozotocin-induced type 2 diabetes
    Comparator
    Vehicle
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 8 weeksAs given in this study (mice).

    Source sentences

    Summary
    We also found that dulaglutide preserved AMP-activated protein kinase α2-dependent mitochondrial homeostasis,
    2 context sentences
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.
  11. 11LabIn vitro (cells)Mechanism

    In stressed neonatal rat ventricular myocytes, dulaglutide improved mitochondrial fragmentation.

    In plain wordsIn cells from newborn rat hearts, dulaglutide improved mitochondrial fragmentation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMyocyte mitochondrial fragmentation
    Study

    ratn: not reported in source

    Neonatal rat ventricular myocytes treated with high glucose plus palmitic acid
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, dulaglutide improved mitochondria fragmentation in myocytes,
    1 context sentence
    Summary · context
    Also, we analyzed the effects of dulaglutide on neonatal rat ventricular myocytes treated with high glucose plus palmitic acid.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 12AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Mechanism

    In diabetic mice, AMP-activated protein kinase α2 knockout almost abolished dulaglutide's cardiac protection.

    In plain wordsIn mice with diabetes, removal of the reported kinase gene almost abolished dulaglutide's heart protection.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseLoss of cardiac protection after AMPK knockout
    Study

    micen: not reported in source

    Wild type and AMP-activated protein kinase α2 mutant mice
    Comparator
    Dulaglutide-treated mice without AMP-activated protein kinase α2 knockout
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    and the protective effects of dulaglutide on diabetic heart was almost abated by AMP-activated protein kinase α2 knockout.
    3 context sentences
    Summary · context
    In addition, wild type and AMP-activated protein kinase α2 mutant mice were used to evaluate the underlying mechanism.
    Summary · context
    Methods and Results We used mice with high-fat diet (HFD)/streptozotocin-induced type 2 diabetes to investigate the effects of dulaglutide upon diabetic cardiac dysfunction.
    Summary · context
    After the onset of diabetes, control and diabetic mice were injected subcutaneously with either dulaglutide (type 2 diabetes-dulaglutide and control-dulaglutide groups) or vehicle (type 2 diabetes-vehicle and control-vehicle groups) for 8 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.